
What would more time between injections mean to your patients?
When stiffness returns too early, the struggle resumes... Use Dysport for symptom* relief that lasts between injections.
*Symptoms of spasticity can include abnormal increase in muscle tone and muscle spasm.
When efficacy wears off, even something as simple as personal hygiene can become a challenge again.
Patient experience:
In an international online survey—Patients Living With Spasticity*— almost a quarter of respondents treated with BoNT-A reported a response of less than 3 months5
*This was a global Internet-based survey, designed in collaboration with the World Federation for NeuroRehabilitation. Data were collected in 29 countries over 13 months from 281 patients diagnosed with spasticity (only inclusion/exclusion criteria; 204 respondents (73%) had been treated with BoNT injections) and encourage to participate by their physician. The survey consisted of multiple-choice questions and was designed to be self-completed by patients and anonymous.5
A History of FDA Approval
Duration of FDA approval is not intended to imply superiority in efficacy or safety of Dysport
Efficacy-AULS
At Week 4, Dysport reduced muscle tone in adult patients with ULS. This improvement lasted beyond the minimum retreatment period of 12 weeks.
In the treatment of adult patients with spasticity, start Dysport for lasting symptom relief1
The majority of patients in the clinical studies were retreated between 12 and 16 weeks; however, some patients had a longer duration of response
Dysport is FDA approved for the treatment of spasticity in patients aged 2 years and older
Study Design:
The efficacy and safety of Dysport were evaluated in a randomized, multicenter, double-blind, placebo-controlled study in 238 adults with upper limb spasticity.
The co-primary efficacy endpoints were mean change in Modified Ashworth Scale (MAS) score in the primary target muscle group (PTMG) (elbow, wrist, or finger flexors) and Physician’s Global Assessment (PGA) of response to treatment between baseline and week 4. MAS score at baseline (mean [SD]): placebo, 3.9 (+/–0.4); Dysport 500 Units, 3.9 (+/–0.5); Dysport 1000 Units, 3.9 (+/–0.4).
Follow-up assessments occurred at weeks 1, 4, and 12; follow-up visits were also permitted at weeks 16, 20, and 24 as needed for retreatment. After 3 months of on-study treatment, patients were given the opportunity to continue open-label treatment with Dysport for up to 5 additional treatment cycles.
Study participants included both botulinum toxin treatment-naïve and -experienced patients

‡Defined as a study participant who had never received any botulinum toxin in the affected upper limb.
Established efficacy
- Dysport 500 Units and Dysport 1,000 Units significantly reduced muscle tone in the primary target muscle group (PTMG)1,2
Reduction from baseline in muscle tone as measured by Modified Ashworth Scale (MAS) at week 41

Week 12 results may represent chance findings, as multiplicity adjustments were not applied; interpret appropriately.
Reduction in muscle tone was seen as early as week 1†
- LS mean change from baseline at week 1: Dysport 1000 Units, –0.9 (P≤0.05 vs placebo); Dysport 500 Units, –0.8 (P≤0.05 vs placebo); placebo, –0.2
- Reduction in muscle tone at week 1 was not a primary endpoint
†Calculations were based on the number of patients responding at each week divided by the total number of patients at week 4.
Physicians reported a significant (P≤0.05) improvement in response to treatment in patients receiving either dose of Dysport at week 4, as assessed by the Physician’s Global Assessment (PGA) of response to treatment (co-primary efficacy endpoint)
- Dysport 1000 Units: 1.8 score
- Dysport 500 Units: 1.4 score
- Placebo: 0.7 score
Most commonly observed adverse reactions (≥4%) were muscular weakness
Time to retreatment
- Use Dysport for symptom relief that lasts between injections — because a long duration of response should matter
- Retreatment (n=147) was between 12 and 16 weeks for 83% of patients; however, some patients had a longer duration of response*1,2
*Patients who remained in the study after week 12 were permitted additional discretionary follow-up at week 16, week 20, and week 24 to assess eligibility for retreatment.
Time to retreatment was not the primary endpoint
In the pivotal trial for adult spasticity, need for retreatment was determined by:
- No longer demonstrating a decrease from baseline of ≥1 grade in MAS score in the PTMG and
- No improvement in PGA (score ≤0) and
- No sign of unacceptable safety risk for next treatment cycle
Investigator discretion based on efficacy and safety criteria, determined need for retreatment for patients demonstrating a decrease from baseline of ≥1 grade in MAS score and/or improvement in PGA [ie, a score ≥+1]
Some patients in clinical studies of spasticity had a longer duration of response, ie, 20 weeks
Repeat Dysport treatment should be administered no sooner than 12 weeks after the previous injection
Efficacy-ALLS
Dysport has an established efficacy in reducing muscle tone of patients with lower limb spasticity at week 4, and improvement could last beyond the minimum retreatment period1,2
In the treatment of adults patients with spasticity, start Dysport for lasting symptom relief1
The majority of patients in the clinical studies were retreated between 12 and 16 weeks; however, some patients had a longer duration of response
Dysport is FDA approved for the treatment of spasticity in patients aged 2 years and older
Study Design
The efficacy of Dysport was evaluated in a randomized, multicenter, double-blind, placebo-controlled study in 381 adults with lower limb spasticity.
The primary efficacy endpoint was muscle tone assessed by LS mean change from baseline in Modified Ashworth Scale (MAS) score at the affected ankle joint at week 4. MAS score at baseline (mean [SD]): placebo, 3.9 (+/–0.5); Dysport 1000 Units, 3.8 (+/–0.5); Dysport 1,500 Units, 3.7 (+/–0.5).
Follow-up assessments occurred at weeks 1, 4, and 12; follow-up visits were also permitted at weeks 16, 20, and 24 as needed for retreatment. After 3 months of on-study treatment, patients were given the opportunity to continue open-label treatment with Dysport.
Study participants included both botulinum toxin treatment-naïve and -experienced patients

†Defined as a study participant who had never received botulinum toxin in the affected lower limb.
Established efficacy
- Dysport 1500 Units significantly reduced muscle tone at affected ankle joint1,2
Most commonly observed adverse reactions (≥5%) were falls, muscular weakness, and pain in extremity
Reduction from baseline in muscle tone as measured by Modified Ashworth Scale (MAS) at week 41
Week 12 results may represent chance findings, as multiplicity adjustments were not applied; interpret appropriately.
Time to retreatment
- Use Dysport for symptom relief that lasts between injections — because a long duration of response should matter
- Retreatment (n=229) was between 12 and 16 weeks for 90% of patients; however, some patients had a longer duration of response1,2

Time to retreatment was not the primary endpoint
In the pivotal trial for adult spasticity, need for retreatment was determined by:
- No longer demonstrating a decrease from baseline of ≥1 grade in MAS score in the primary targeted muscle group and
- No improvement in Physician’s Global Assessment (PGA) (score ≤0) and
- No sign of unacceptable safety risk for next treatment cycle
Investigator discretion based on efficacy and safety criteria, determined need for retreatment for patients demonstrating a decrease from baseline of ≥1 grade in MAS score and/or improvement in PGA [ie, a score ≥+1]
Some patients in clinical studies of spasticity had a longer duration of response, ie, 20 weeks
Repeat Dysport treatment should be administered no sooner than 12 weeks after the previous injection
Patients who remained in the study after week 12 were permitted additional discretionary follow-up at week 16, week 20, and week 24 to assess eligibility for retreatment.
Register
Interested in adding your practice to our Dysport Doctor Locator directory or updating your listing?
Register for Doctor Locator when you sign up for C.L.I.M.B.®
See eligibility criteria at www.CLIMB-training.com
The C.L.I.M.B. educational learning platform is a multitier learning continuum designed to accommodate physicians new to and experienced with botulinum toxin therapy. This educational curriculum is designed to help physicians across all levels improve their clinical skills involving the appropriate use of Dysport. Visit www.CLIMB-training.com to learn more!